**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 45741

**Manuscript type:** MINIREVIEWS

**Ultrasound imaging of abdominal sarcoidosis: State of the art**

Tana C e*t al.* US in abdominal SA

Claudio Tana, Cosima Schiavone, Andrea Ticinesi, Fabrizio Ricci, Maria Adele Giamberardino, Francesco Cipollone, Mauro Silingardi, Tiziana Meschi, Christoph F Dietrich

**Claudio Tana, Andrea Ticinesi, Tiziana Meschi,** Internal Medicine and Critical Subacute Care Unit, Medicine Geriatric-Rehabilitation Department, and Department of Medicine and Surgery, University-Hospital of Parma, Parma 43126, Italy

**Cosima Schiavone,** Department of Internistic Ultrasound, “G. D’Annunzio” University of Chieti, Chieti 66100, Italy

**Fabrizio Ricci,** Department of Imaging and Clinical Sciences, Institute for Advanced Biomedical Technologies, “G. D’Annunzio” University of Chieti, Chieti 66100, Italy

**Maria Adele Giamberardino,** Geriatrics Clinic, Department of Medicine and Science of Aging, “G. D’Annunzio” University of Chieti, Chieti 66100, Italy

**Francesco Cipollone**, Medical Clinic, Department of Medicine and Science of Aging, “G. D’Annunzio” University of Chieti, Chieti 66100, Italy

**Mauro Silingardi,** Internal Medicine Unit, Maggiore Hospital of Bologna, Bologna 40133, Italy

**Christoph F Dietrich,** Caritas-Krankenhaus Bad Mergentheim, Academic Teaching Hospital of the University of Würzburg, Bad Mergentheim D-97980, Germany

**ORCID number:** Claudio Tana (0000-0002-9162-7866); Cosima Schiavone (0000-0002-8453-4936); Andrea Ticinesi (0000-0001-9171-8592); Fabrizio Ricci (0000-0002-1401-6623); Maria Adele Giamberardino (0000-0002-3889-4551); Francesco Cipollone (0000-0002-5993-9341); Mauro Silingardi (0000-0002-9518-8725); Tiziana Meschi (0000-0002-7538-6863); Christoph F Dietrich (0000-0001-6015-6347).

**Author contributions:** All authors equally contributed to this paper with the conception, and design of the study, literature review and analysis, drafting and critical revision, and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript Source:** Invited manuscript

**Corresponding author:** **Claudio Tana, MD, Doctor, Medical Assistant,** Internal Medicine and Subacute Care Unit, Medicine-Geriatric Rehabilitation Department,University Hospital of Parma, Via Antonio Gramsci 14, Parma 43126, Italy.[ctana@ao.pr.it](mailto:ctana@ao.pr.it)

**Telephone:** +39-521-704316

**Fax:** +39-521-704316

**Received:** January 21, 2019

**Peer-review started:** January 21, 2019

**First decision:** February 13, 2019

**Revised:** March 8, 2019

**Accepted:** March 16, 2019

**Article in press:** March 16, 2019

**Published online:** April 6, 2019

**Abstract**

Since it has been recognized that sarcoidosis (SA) is not an exclusive disorder of the lungs but can also affect other organs such as the liver and spleen, efforts have been made to define specific imaging criteria for the diagnosis of the single organ involvement, and the concept has been reinforced that the exclusion of alternative causes is important to achieve the correct diagnosis. Ultrasound (US) is a useful tool to evaluate patients with suspected abdominal SA, such as of the liver, spleen, kidney, pancreas and other organs, showing findings such as organomegaly, focal lesions and lymphadenopathy. While the diagnosis of abdominal SA is more predictable in the case of involvement of other organs (*e.g.* lungs), the problem is more complex in the case of isolated abdominal SA. The recent use of contrast-enhanced ultrasound and endoscopic ultrasound elastography has provided additional information about the enhancement patterns and tissue rigidity in abdominal SA. Here we critically review the role of US in abdominal SA, reporting typical findings and limitations of current evidence and by discussing future perspectives of study.

**Key words:** Sarcoidosis; Sarcoid lesions; Granulomatous disorders; Liver; Spleen; Rare diseases; Ultrasound; Contrast-enhanced ultrasound

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Ultrasound (US) is useful to evaluate patients with suspected abdominal sarcoidosis (SA), showing some findings such as organomegaly, hypoechoic lesions and adenopathy. While the diagnosis of abdominal SA is more predictable in the case of involvement of other organs (*e.g.* lungs) the problem is more complex in the case of isolated abdominal SA. The recent use of contrast-enhanced ultrasound and endoscopic ultrasound elastography has provided additional information about the enhancement patterns and tissue rigidity in abdominal SA. Our objective was to critically review the role of US in abdominal SA, reporting characteristic findings and limitations of current evidence and discussing future perspectives of study.

**Citation:** Tana C, Schiavone C, Ticinesi A, Ricci F, Giamberardino MA, Cipollone F, Silingardi M, Meschi T, Dietrich CF. Ultrasound imaging of abdominal sarcoidosis: State of the art. *World J Clin Cases* 2019; 7(7): 809-818

**URL:** https://www.wjgnet.com/2307-8960/full/v7/i7/809.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v7.i7.809

**INTRODUCTION**

Since the first evidence in 1899 of sarcoid lesions provided by the Norwegian dermatologist Caesar Boeck[1,2], it has been recognized that sarcoidosis (SA) is not an exclusive disorder of a single organ, but can affect virtually every tissue, manifesting with clinically silent or symptomatic granulomatous lesions[3,4]. In this context the term “great chameleon” was created, indicating a non-specific disease with an undefined etiology that mimicks various disorders in the clinical picture or imaging[5-8].

In the last few years, efforts have been made to define imaging criteria for the diagnosis of specific organ involvement, and the concept has been reinforced that the exclusion of alternative causes is important to achieve the correct diagnosis; a thorough clinical and laboratory assessment is therefore suggested before establishing any imaging approach [9-11]. Conventional US can reveal some useful imaging findings, and the recent advent of novel US techniques, such as contrast-enhanced ultrasound (CEUS) and endoscopic ultrasound (EUS) elastography, has provided more information about the abdominal involvement in this uncommon disease.

**SARCOIDOSIS, A DISORDER NOT EXCLUSIVE TO THE LUNGS**

Among all granulomatous disorders, SA most often affects the lungs and intra-thoracic lymph nodes by manifesting with restrictive lung disease[12]. However, SA can also involve abdominal organs, such as the liver and spleen, in a non-negligible percentage that varies according to the presence or absence of overt symptoms[13]. In particular, the symptomatic involvement of liver and spleen is estimated to be around 10%-25 % and 5%-10% of cases, respectively but asymptomatic cases can be higher[14]. A computed tomography (CT) analysis conducted by Warshauer *et al*[15] in 32 patients with abdominal SA documented a high prevalence of organomegaly and adenopathy (76%). Virtually, there is no organ that is spared from SA[16], and the high potential of ubiquitous body involvement raises the problem of the great diagnostic challenge in patients with suspected abdominal SA, whic may occur in a percentage higher than that documented clinically. The issue becomes even more complex because patients with traditional pulmonary SA do not usually undergo extensive imaging evaluation unless they present significant abnormalities at liver tests[17].

**ULTRASOUND ASSESSMENT OF HEPATOSPLENIC SARCOIDOSIS**

Although the evidence of hepatosplenic SA at imaging can be limited if there is only a microscopic involvement, ultrasound (US) can be useful to detect some macroscopic findings. Low cost, wide availability and no radiation exposure are some of the main advantages of this method, and routine inclusion of this examination in patients with suspected abdominal SA could be useful to screen the involvement of the liver and spleen[17]. However, several other disorders can lead to a liver test dysfunction, such as nonalcoholic liver disease and nonalcoholic steatohepatitis[18], and the two disorders can coexist in such a way as to make the imaging distinction even more complicated. Nevertheless, a first imaging evaluation with US should be included in the routine assessment of patients with suspected abdominal SA, in particular if there is clinical evidence of hepatic dysfunction or liver test abnormalities[17].

Second imaging approaches include contrast-enhanced CT, magnetic resonance imaging (MRI) and 18F-FDG PET/CT, which have shown a good diagnostic reliability in the assessment of abdominal SA[19]

***Liver disease***

US can reveal several non-specific findings in patients with SA of the liver, such as hepatomegaly or bright liver appearance, and can document a significant inhomogeneity of the parenchyma with a coarse nodular pattern, suggesting a patchy granulomatous infiltration of the parenchyma[17,20]. Given their nonspecific aspect, however, these findings can be easily misdiagnosed with some features that are observed in other very common disorders, such as fatty liver disease and hepatic cirrhosis[20].

The presence of prominent, various-sized nodules can be documented by showing multiple and rounded hypoechoic lesions. Previous US studies have demonstrated that these nodules usually have no specific size and form but are characteristically hypovascular on Doppler US. The features of these lesions have already been discussed and illustrated[15,17,21]. A significant number of disorders (both benign and malignant) enter the differential diagnosis with these lesions, including pseudotumours and tuberculosis[22], and US-guided biopsy can be useful to reveal the presence of non-caseating granulomas, which represent a specific hallmark of the disease and are useful for the definitive diagnosis if the clinical picture or imaging is non- specific or inconclusive[23].

***Splenic involvement***

The involvement of the spleen is similar to that of the liver, manifesting with non-specific organ enlargement or hypovascular nodules of various size. In contrast, the lesions can show different degrees of echogenecity (hypo, iso or hyper), possibly according to the different degree of fibrosis of the nodules. However, these lesions can be easily misdiagnosed as nodularities from other disorders; in particular, those that are hypoechoic can be wrongly interpreted as lesions from splenic lymphoma, a disorder that is characterized by a hypoechoic appearance of their nodules[24-26]. Here again, the problem becomes even more challenging when the two disorders coexist[27]. Several studies have, in fact, documented a strong correlation between SA and malignancy (the so-called SA-lymphoma syndrome) and the coexistence of sarcoid and lymphomatous tissue can result in great difficulty of differential diagnosis[28]. Sometimes a definite diagnosis is reached only through histological examination, a procedure that would inevitably lead to invasive splenectomy.

**LYMPH NODE EVALUATION**

Another US finding of abdominal SA is the presence of enlarged lymph nodes, which has been described in up to 76% of the cases as inhomogeneous hypoechoic lesions sized generally 1-2 cm and located in periportal, paracaval, paraaortic and celiac sites. They can be interpreted erroneously as the sign of chronic virus hepatitis C[29], primary biliary cirrhosis[30] and primary sclerosing cholangitis[31]; a correct interpretation is therefore mandatory to avoid wrong therapeutic approaches[32]. Unlike these disorders, lymph nodes enlargement in SA can reach higher sizes (up to 6 cm) and show tumor-like patterns, with no clear evidence of hilar lymph nodes[17,33].

**PANCREATIC INVOLVEMENT FROM SARCOID LESIONS**

The pancreas is rarely involved in SA (1%-3% of cases), and focal sarcoid lesions have been reported in less than 50 cases in the literature[34].

Main imaging findings are the presence of hypoechoic and hypovascular focal masses within the parenchyma, sometimes associated with focal or global common bile and pancreatic ducts dilatation[35]. Size can vary significantly and large hypoechoic masses can be found exceptionally (Figure 1A).

These findings can mimic the imaging features observed in tuberculosis of the pancreas[36]. Further imaging techniques (CEUS and EUS elastography) can be useful to reveal some useful patterns (Figure 1B, see below).

**RENAL SARCOIDOSIS**

Renal involvement from SA is estimated to be around 25%-30% among all cases, and manifests most commonly with granulomatous interstitial nephritis and disturbances in calcium homeostasis with occurrence of nephrolithiasis and nephrocalcinosis[37]. The direct involvement of kidney by granulomatous tissue and the presence of solid masses, however, are extremely rare. Pseudotumours raise significant problems of differential diagnosis with malignant nodules such as renal cell carcinoma and lymphoma, because they can manifest with similar imaging findings. Such nodules can present as single or multiple hypoechoic masses, hypovascular on Doppler US[38]. They can grow within renal parenchyma (Figure 2) or be characterized by a focal and exophytic growth[39,40].

For the first time, we found a case of ring-like echogenic pattern determined by a sarcoid lesion of the parenchyma (Figure 3). Also this pattern can be misdiagnosed with that observed in focal malignant lesions.

**THE DIAGNOSTIC SUPPORT OF CONTRAST-ENHANCED ULTRASOUND**

CEUS has demonstrated a high accuracy to detect and characterize the nature of a large amount of liver and splenic nodules[41,42]. Despite this, there are few studies aimed at assessing CEUS patterns in granulomatous infiltration such as from SA, and most evidence derives from large but heterogeneous studies including nodules of different histology[43]. The use of CEUS in liver SA can reveal a variable nodular enhancement and progressive hypoenhancement in the arterial and portal-venous late phases, respectively (Figure 4)[17,44]. Sometimes the nodules can be hyperenhancing for more than 2 min (Figure 5).

For nodular lesions of the spleen, CEUS can show a progressive hypoenhancement pattern in both the arterial and parenchymal phases, with a higher contrast diffusion toward parenchyma in this phase (Figure 6)[45].

Other enhancement patterns have also been documented (*e.g.,* rim-like, homogeneous, dotted) and, in particular cases with peripheral or rim-like enhancement in the arterial phase followed by a rapid washout in the parenchymal phase, can mimick the patterns observed for neoplastic lesions, raising great problems of differential diagnosis with solid cancers and hematologic disorders[46,47].

Stang *et al*[48] have previously reported two cases of splenic SA with diffuse and homogeneous arterial enhancement followed by a progressive hypoenhancement in the parenchymal phase. In this context, the exclusive use of CEUS to confirm the presence of isolated splenic SA can fail, making histopathological examination necessary[49,50].

Lymph nodes enlargement can also be detected by CEUS, by showing a progressive homogeneous enhancement. This pattern can be useful to confirm the benign nature of the lymph node involvement[51].

In contrast, focal lesions of the pancreas show a rapid and transitory enhancement followed by progressive hypoenhancement; a histological examination is thus important to confirm the benign nature of the lesion and to exclude the presence of malignant tissue[35]. There is low evidence instead about the CEUS patterns of kidney SA[40].

In this complex scenario, a useful diagnostic algorithm can involve the integration of clinical, laboratory and imaging findings if the abdominal involvement from SA is associated with other clinical manifestations (*e.g.* lung disease). The additional diagnostic support of CEUS could be useful to confirm the presence of the lesions. In the case of suspected isolated hepatosplenic or pancreatic SA, however, the additional use of biopsy is strongly advisable to achieve the correct diagnosis, because many common (and also harmful) conditions can be easily misdiagnosed with SA.

There is a great need for studies aimed at evaluating patients with isolated abdominal SA, because, given the pleomorphic nature of SA, it is not difficult to hypothesize other CEUS patterns.

**FINDINGS ON ENDOSCOPIC ULTRASOUND ELASTOGRAPHY**

Although the evidence derives from single case reports or small case series, the greater diffusion of EUS elastography has provided additional information about the tissue rigidity of sarcoid lesions in abdominal SA.

Liver lesions can show a diffuse blue hard pattern within and around the single masses that correlates well with the granulomatous tissue at biopsy[52].

Lymph node enlargement, instead, shows a mixed, predominantly green pattern at EUS elastography, with a 3-point score (range 1-5 soft *vs* hard/solid, respectively)[53].

Similar patterns of rigidity are observed for pancreatic lesions, and both soft and hard tissues are documented on EUS elastography (Figure 1B). These findings suggest the co-existence of mixed tissue components, which are peculiar to disorders such as SA that show both fibrotic tissue and non-caseating granulomas[53]. Table 1 shows the main US, CEUS and EUS findings of abdominal SA.

**ADVANTAGES AND LIMITS OF US VERSUS OTHER IMAGING METHODS**

US is an inexpensive and rapidly available method that can be performed at patient’s bedside. The use of ultrasound contrast agents (UCAs) can improve the detection rate of suspected focal lesions, with a lower risk of hypersensitivity reactions than that associated with X-ray contrast agents, and similar to that encountered with MRI contrast agents[49]. The safer profile of UCAs allows repeating the evaluation of the nodules also more than one time for session, giving more opportunities to study the characteristics of the lesions. However, conventional sonographic methods are operator-dependent and have generally lower specificity and sensitivity than other imaging methods such as CT. This is a great limit of the B-mode US evaluation in cases of suspected abdominal SA, because some lesions can be missed at a first imaging evaluation.

**CONCLUSION**

The involvement of abdominal organs by SA is a possible occurrence that should be taken into consideration in patients with a diagnosis of SA. An increase in US examinations as the screening test in asymptomatic patients could be useful to detect asymptomatic nodules, particularly if there are blood test abnormalities indicating for instance liver dysfunction. The challenge remains in the case of isolated hepatosplenic SA, which is often found by chance and is associated with a significant risk of misdiagnosis with other conditions if an appropriate diagnostic approach is not performed.

Due to the limited number of cases of abdominal SA that have been investigated with CEUS and elastography, definite conclusions and recommendations are not possible so far. The wider diffusion of these techniques and the increasing evidence about the diagnostic accuracy for nodular lesions have led to a great need also to assess patients with rare conditions such as SA. In the future, we expect more tailored studies in these patients, also to evaluate the diagnostic accuracy of CEUS and elastography in order to give a presumptive characterization of the nature of nodules, which could be useful to guide (or sometimes avoid) invasive approaches, such as histological examination.

**REFERENCES**

1 **Boeck C.** Multiple benign sarcoid of the skin. *J Cutan Genitourin Dis* 1899; **17**: 543-550

2 **Tchernev G**, Cardoso JC, Chokoeva AA, Verma SB, Tana C, Ananiev J, Gulubova M, Philipov S, Kanazawa N, Nenoff P, Lotti T, Wollina U. The "mystery" of cutaneous sarcoidosis: facts and controversies. *Int J Immunopathol Pharmacol* 2014; **27**: 321-330 [PMID: 25280023 DOI: 10.1177/039463201402700302]

3 **Martin WJ 2nd**, Iannuzzi MC, Gail DB, Peavy HH. Future directions in sarcoidosis research: summary of an NHLBI working group. *Am J Respir Crit Care Med* 2004; **170**: 567-571 [PMID: 15142870 DOI: 10.1164/rccm.200308-1073WS]

4 **Mañá J**, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, Llatjos R, García O, Martínez-Yélamos S, Vicens-Zygmunt V, Gámez C, Pujol R, Corbella X. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. *Medicine (Baltimore)* 2017; **96**: e7595 [PMID: 28723801 DOI: 10.1097/MD.0000000000007595]

5 **Chen ES**, Moller DR. Etiologies of Sarcoidosis. *Clin Rev Allergy Immunol* 2015; **49**: 6-18 [PMID: 25771769 DOI: 10.1007/s12016-015-8481-z]

6 **Valeyre D**, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. *Lancet* 2014; **383**: 1155-1167 [PMID: 24090799 DOI: 10.1016/S0140-6736(13)60680-7]

7 **Chokoeva AA**, Tchernev G, Tana C, Ananiev J, Wollina U. Sarcoid-like pattern in a patient with tuberculosis. *J Biol Regul Homeost Agents* 2014; **28**: 783-788 [PMID: 25620187]

8 **Tana C**, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Fioranelli M, Roccia MG, Maximov GK, Silingardi M. Pulmonary and abdominal sarcoidosis, the great imitators on imaging? *J Biol Regul Homeost Agents* 2016; **30**: 45-48 [PMID: 27373134]

9 **Morgenthau AS**, Iannuzzi MC. Recent advances in sarcoidosis. *Chest* 2011; **139**: 174-182 [PMID: 21208877 DOI: 10.1378/chest.10-0188]

10 **Chen ES**, Moller DR. Sarcoidosis--scientific progress and clinical challenges. *Nat Rev Rheumatol* 2011; **7**: 457-467 [PMID: 21750528 DOI: 10.1038/nrrheum.2011.93]

11 **Chokoeva AA**, Tchernev G, Tana M, Tana C. Exclusion criteria for sarcoidosis: A novel approach for an ancient disease? *Eur J Intern Med* 2014; **25**: e120 [PMID: 25457837 DOI: 10.1016/j.ejim.2014.10.009]

12 **Hirche TO**, Hirche H, Cui XW, Wagner TO, Dietrich CF. Ultrasound evaluation of mediastinal lymphadenopathy in patients with sarcoidosis. *Med Ultrason* 2014; **16**: 194-200 [PMID: 25110759 DOI: 10.11152/mu.2013.2066.163.2hh]

13 **Palmucci S**, Torrisi SE, Caltabiano DC, Puglisi S, Lentini V, Grassedonio E, Vindigni V, Reggio E, Giuliano R, Micali G, Caltabiano R, Andreula C, Foti PV, Ettorre GC, Walsh SL, Vancheri C. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. *Insights Imaging* 2016; **7**: 571-587 [PMID: 27222055 DOI: 10.1007/s13244-016-0495-4]

14 **Folz SJ**, Johnson CD, Swensen SJ. Abdominal manifestations of sarcoidosis in CT studies. *J Comput Assist Tomogr* 1995; **19**: 573-579 [PMID: 7622687]

15 **Warshauer DM**, Molina PL, Hamman SM, Koehler RE, Paulson EK, Bechtold RE, Perlmutter ML, Hiken JN, Francis IR, Cooper CJ. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. *Radiology* 1995; **195**: 757-762 [PMID: 7754007 DOI: 10.1148/radiology.195.3.7754007]

16 **Tana C**, Wegener S, Borys E, Pambuccian S, Tchernev G, Tana M, Giamberardino MA, Silingardi M. Challenges in the diagnosis and treatment of neurosarcoidosis. *Ann Med* 2015; **47**: 576-591 [PMID: 26469296 DOI: 10.3109/07853890.2015.1093164]

17 **Tana C**, Dietrich CF, Schiavone C. Hepatosplenic sarcoidosis: contrast-enhanced ultrasound findings and implications for clinical practice. *Biomed Res Int* 2014; **2014**: 926203 [PMID: 25215299 DOI: 10.1155/2014/926203]

18 **Harder H**, Büchler MW, Fröhlich B, Ströbel P, Bergmann F, Neff W, Singer MV. Extrapulmonary sarcoidosis of liver and pancreas: a case report and review of literature. *World J Gastroenterol* 2007; **13**: 2504-2509 [PMID: 17552036 DOI: 10.3748/wjg.v13.i17.2504]

19 **Tana C.** FDG-PET Imaging in Sarcoidosis. *Curr Med Imaging Rev* 2019; **15**: 2-3 [DOI: 10.2174/157340561501181207091552]

20 **Sartori S**, Galeotti R, Calia N, Gualandi M, Nielsen I, Trevisani L, Ceccotti P, Abbasciano V. Sonographically guided biopsy and sonographic monitoring in the diagnosis and follow-up of 2 cases of sarcoidosis with hepatic nodules and inconclusive thoracic findings. *J Ultrasound Med* 2002; **21**: 1035-1039 [PMID: 12216751 DOI: 10.7863/jum.2002.21.9.1035]

21 **Tana C**, Silingardi M, Dietrich CF. New trends in ultrasound of hepatosplenic sarcoidosis. *Z Gastroenterol* 2015; **53**: 283-284 [PMID: 25860577 DOI: 10.1055/s-0034-1399122]

22 **Schuessler G**, Fellbaum C, Fauth F, Jacobi V, Schmidt-Matthiesen A, Ignee A, Dietrich CF. [The infammatory pseudotumour -- an unusual liver tumour]. *Ultraschall Med* 2006; **27**: 273-279 [PMID: 16767617 DOI: 10.1055/s-2005-858530]

23 **Thanos L**, Zormpala A, Brountzos E, Nikita A, Kelekis D. Nodular hepatic and splenic sarcoidosis in a patient with normal chest radiograph. *Eur J Radiol* 2002; **41**: 10-11 [PMID: 11750146 DOI: 10.1016/S0720-048X(01)00375-8]

24 **Saboo SS**, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N, Jagannathan JP. Spleen in haematological malignancies: spectrum of imaging findings. *Br J Radiol* 2012; **85**: 81-92 [PMID: 22096219 DOI: 10.1259/bjr/31542964]

25 **Wan YL**, Cheung YC, Lui KW, Tseng JH, Lee TY. Ultrasonographic findings and differentiation of benign and malignant focal splenic lesions. *Postgrad Med J* 2000; **76**: 488-493 [PMID: 10908377 DOI: 10.1136/pmj.76.898.488]

26 **Ignee A**, Cui X, Hirche T, Demolo C, Barreiros AP, Schuessler G, Dietrich CF. Percutaneous biopsies of splenic lesions--a clinical and contrast enhanced ultrasound based algorithm. *Clin Hemorheol Microcirc* 2014; **58**: 529-541 [PMID: 24448731 DOI: 10.3233/CH-141813]

27 **Oskuei A**, Hicks L, Ghaffar H, Hoffstein V. Sarcoidosis-lymphoma syndrome: a diagnostic dilemma. *BMJ Case Rep* 2017; **2017** [PMID: 29246929 DOI: 10.1136/bcr-2017-220065]

28 **Tana C**, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C. Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? *Int J Immunopathol Pharmacol* 2013; **26**: 305-313 [PMID: 23755746 DOI: 10.1177/039463201302600204]

29 **Dietrich CF**, Lee JH, Herrmann G, Teuber G, Roth WK, Caspary WF, Zeuzem S. Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C. *Hepatology* 1997; **26**: 467-472 [PMID: 9252160 DOI: 10.1002/hep.510260230]

30 **Dietrich CF**, Leuschner MS, Zeuzem S, Herrmann G, Sarrazin C, Caspary WF, Leuschner UF. Peri-hepatic lymphadenopathy in primary biliary cirrhosis reflects progression of the disease. *Eur J Gastroenterol Hepatol* 1999; **11**: 747-753 [PMID: 10445795]

31 **Hirche TO**, Russler J, Braden B, Schuessler G, Zeuzem S, Wehrmann T, Seifert H, Dietrich CF. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. *Int J Colorectal Dis* 2004; **19**: 586-594 [PMID: 15088111 DOI: 10.1007/s00384-004-0598-0]

32 **Cui XW**, Jenssen C, Saftoiu A, Ignee A, Dietrich CF. New ultrasound techniques for lymph node evaluation. *World J Gastroenterol* 2013; **19**: 4850-4860 [PMID: 23946589 DOI: 10.3748/wjg.v19.i30.4850]

33 **Lyttkens K**, Prytz H, Forsberg L, Hederström E, Hägerstrand I. Ultrasound, hepatic lymph nodes and primary biliary cirrhosis. *J Hepatol* 1992; **15**: 136-139 [PMID: 1506630 DOI: 10.1016/0168-8278(92)90025-K]

34 **Bihun T**, Diaz Y, Wenig S. Granulomatous Pancreas: A Case Report of Pancreatic Sarcoid. *Case Rep Gastrointest Med* 2017; **2017**: 1620392 [PMID: 29348948 DOI: 10.1155/2017/1620392]

35 **Azemoto N**, Kumagi T, Koizumi M, Kuroda T, Yamanishi H, Ohno Y, Imamura Y, Takeshita E, Soga Y, Ikeda Y, Onji M, Hiasa Y. Diagnostic Challenge in Pancreatic Sarcoidosis Using Endoscopic Ultrasonography. *Intern Med* 2018; **57**: 231-235 [PMID: 29033431 DOI: 10.2169/internalmedicine.9084-17]

36 **Dong Y**, Jürgensen C, Puri R, D'Onofrio M, Hocke M, Wang WP, Atkinson N, Sharma M, Dietrich CF. Ultrasound imaging features of isolated pancreatic tuberculosis. *Endosc Ultrasound* 2018; **7**: 119-127 [PMID: 28721972 DOI: 10.4103/2303-9027.210901]

37 **Bergner R**, Löffler C. Renal sarcoidosis: approach to diagnosis and management. *Curr Opin Pulm Med* 2018; **24**: 513-520 [PMID: 29965860 DOI: 10.1097/MCP.0000000000000504]

38 **Gezer NS**, Başara I, Altay C, Harman M, Rocher L, Karabulut N, Seçil M. Abdominal sarcoidosis: cross-sectional imaging findings. *Diagn Interv Radiol* 2015; **21**: 111-117 [PMID: 25512071 DOI: 10.5152/dir.2014.14210]

39 **Heldmann M**, Behm W, Reddy MP, Bozeman C, Welman G, Abreo F, Minagar A. Pseudotumoral renal sarcoid: MRI, PET, and MDCT appearance with pathologic correlation. *AJR Am J Roentgenol* 2005; **185**: 697-699 [PMID: 16120920 DOI: 10.2214/ajr.185.3.01850697]

40 **Lockhart ME**, Smith JK, Kenney PJ, Urban DA. Pseudotumorous renal involvement of sarcoidosis. *J Urol* 2001; **165**: 895 [PMID: 11176498]

41 **Dietrich CF**, Tana C, Caraiani C, Dong Y. Contrast enhanced ultrasound (CEUS) imaging of solid benign focal liver lesions. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 479-489 [PMID: 29658347 DOI: 10.1080/17474124.2018.1464389]

42 **Berzigotti A**, Ferraioli G, Bota S, Gilja OH, Dietrich CF. Novel ultrasound-based methods to assess liver disease: The game has just begun. *Dig Liver Dis* 2018; **50**: 107-112 [PMID: 29258813 DOI: 10.1016/j.dld.2017.11.019]

43 **Sidhu PS**, Cantisani V, Dietrich CF, Gilja OH, Saftoiu A, Bartels E, Bertolotto M, Calliada F, Clevert DA, Cosgrove D, Deganello A, D'Onofrio M, Drudi FM, Freeman S, Harvey C, Jenssen C, Jung EM, Klauser AS, Lassau N, Meloni MF, Leen E, Nicolau C, Nolsoe C, Piscaglia F, Prada F, Prosch H, Radzina M, Savelli L, Weskott HP, Wijkstra H. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). *Ultraschall Med* 2018; **39**: e2-e44 [PMID: 29510439 DOI: 10.1055/a-0586-1107]

44 **Stryckers M**, Voet D, Vogelaers D, Afschrift M, Verstraete K, Van Belle S. Contrast-enhanced ultrasonography in hepatosplenic sarcoidosis. *Acta Clin Belg* 2011; **66**: 429-431 [PMID: 22338306 DOI: 10.2143/ACB.66.6.2062609]

45 **Yu X**, Yu J, Liang P, Liu F. Real-time contrast-enhanced ultrasound in diagnosing of focal spleen lesions. *Eur J Radiol* 2012; **81**: 430-436 [PMID: 21273021 DOI: 10.1016/j.ejrad.2010.12.052]

46 **Tana C**, Iannetti G, Mezzetti A, Schiavone C. Splenic sarcoidosis remains a diagnostic challenge. *J Clin Ultrasound* 2014; **42**: 156 [PMID: 24436217 DOI: 10.1002/jcu.22131]

47 **von Herbay A**, Barreiros AP, Ignee A, Westendorff J, Gregor M, Galle PR, Dietrich C. Contrast-enhanced ultrasonography with SonoVue: differentiation between benign and malignant lesions of the spleen. *J Ultrasound Med* 2009; **28**: 421-434 [PMID: 19321670 DOI: 10.7863/jum.2009.28.4.421]

48 **Stang A**, Keles H, Hentschke S, von Seydewitz CU, Dahlke J, Malzfeldt E, Braumann D. Differentiation of benign from malignant focal splenic lesions using sulfur hexafluoride-filled microbubble contrast-enhanced pulse-inversion sonography. *AJR Am J Roentgenol* 2009; **193**: 709-721 [PMID: 19696284 DOI: 10.2214/AJR.07.3988]

49 **Chiorean L**, Tana C, Braden B, Caraiani C, Sparchez Z, Cui XW, Baum U, Dietrich CF. Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines. *Med Princ Pract* 2016; **25**: 399-407 [PMID: 27318740 DOI: 10.1159/000447670]

50 **Tana C**, Iannetti G, D'Alessandro P, Tana M, Mezzetti A, Schiavone C. Pitfalls of contrast-enhanced ultrasound (CEUS) in the diagnosis of splenic sarcoidosis. *J Ultrasound* 2013; **16**: 75-80 [PMID: 24294346 DOI: 10.1007/s40477-013-0013-1]

51 **Chiorean L**, Cui XW, Klein SA, Budjan J, Sparchez Z, Radzina M, Jenssen C, Dong Y, Dietrich CF. Clinical value of imaging for lymph nodes evaluation with particular emphasis on ultrasonography. *Z Gastroenterol* 2016; **54**: 774-790 [PMID: 27529528 DOI: 10.1055/s-0042-108656]

52 **Rustemovic N**, Hrstic I, Opacic M, Ostojic R, Jakic-Razumovic J, Kvarantan M, Pulanic R, Vucelic B. EUS elastography in the diagnosis of focal liver lesions. *Gastrointest Endosc* 2007; **66**: 823-4; discussion 824 [PMID: 17681503 DOI: 10.1016/j.gie.2007.06.047]

53 **Rahimi E**, Younes M, Zhang S, Thosani N. Endoscopic ultrasound elastography to diagnose sarcoidosis. *Endosc Ultrasound* 2016; **5**: 212-214 [PMID: 27386482 DOI: 10.4103/2303-9027.183972]

**P-Reviewer:** Sun SY, Sipahi AM **S-Editor:** Dou Y **L-Editor:** A **E-Editor:** Wu YXJ

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Italy

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C


Grade D (Fair): 0


Grade E (Poor): 0


**Figure 1 Nodular hypoechoic lesion of the pancreas.** A, B: Nodular hypoechoic lesion of the pancreas showing a mixed pattern (soft versus hard as red and yellow, green and blue colors, respectively) at endoscopic ultrasound elastography.

**Figure 2 Hypoechoic lesion of the kidney that was revealed as focal nodule from sarcoidosis (arrow).**

**Figure 3 Ring-like echogenic pattern determined by a sarcoid lesion of the renal parenchyma (markers).**

**Figure 4 Progressive hypoenhancement in the arterial and portal-venous late phases, respectively, of a nodular sarcoid lesion of the liver.**

**Figure 5 A rare case of hyperenhancing lesion in arterial, portal-venous and late phase.**

**Figure 6 Two different cases of hypoenhancing nodules from sarcoidosis of the spleen.**

**Table 1 Main ultrasound and endoscopic ultrasound findings of abdominal sarcoidosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **US** | **CEUS** | **EUS elastography** |
| Liver | (1) Hepatomegaly; (2) Coarse nodular pattern; (3) Hypoechoic and hypovascular nodules | Variable nodular enhancement and progressive hypoenhancement in the arterial and portal-venous late phases, respectively | Blue hard pattern within and around the single masses that correlate well with the granulomatous tissue at biopsy |
| Spleen | (1) Organ enlargement; (2) Hypo, iso or hyperechoic, hypovascular nodules | (1) Progressive hypoenhancement in both the arterial and parenchymal phases, with a higher contrast diffusion toward parenchyma in this phase; (2) Other patterns: rim-like, homogeneous, dotted | N/A |
| Lymph nodes | (1) Lymphadenopathy; (2) Hypoechoic 1-2 cm sized nodules | Progressive homogeneous enhancement, suggesting a benign pattern | Mixed, predominantly green pattern |
| Pancreas | (1) Focal hypoechoic and hypovascular masses; (2) Pancreatic duct dilatation | Rapid and transitory enhancement followed by progressive hypoenhancement, mimicking a malignant pattern | Both soft and hard tissues, suggesting the co-existence of mixed tissue components |
| Kidneys | (1) Pseudotumors as hypoechoic and hypovascular masses; (2) Ring-like echogenic pattern | Hypoenhancing lesions | N/A |

US: Ultrasound; CEUS: Contrast-enhanced ultrasound; EUS: Endoscopic ultrasound.